ABVX

Abivax S.a.

A French biotechnology company developing once-daily oral medicines for chronic inflammatory diseases, led by its drug candidate obefazimod for ulcerative colitis and Crohn's disease. It was founded in Paris in 2013 by immunologist Philippe Pouletty, who brought together three French biotech firms to build it. The name hints at its surprising start: obefazimod was first researched as an anti-HIV compound, and its anti-inflammatory powers were discovered by accident along the way.

Sponsored American Depositary Shares representing ordinary shares of Abivax S.A.